CD8A and neoplasm: The first one was 4-1BB aptamer used to deliver siRNA to T cells, aiming to disrupt mTOR pathway and attenuate IL-2R signaling in CD8+ T cells, which, in turn, leads to CD8+ T cells persistence inside the tumor site and its elimination [49].